BG
SGMO

Bellevue Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bellevue Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,850,000
Closed -$36.4M – 226
2020
Q3 		$36.4M Hold
3,850,000
– – 0.5% 57
2020
Q2 		$34.5M Hold
3,850,000
– – 0.49% 52
2020
Q1 		$24.5M Hold
3,850,000
– – 0.48% 57
2019
Q4 		$32.2M Buy
3,850,000
+200,000
+5% +$1.84M 0.51% 49
2019
Q3 		$33M Hold
3,650,000
– – 0.61% 43
2019
Q2 		$39.3M Buy
+3,650,000
New +$38.8M 0.67% 38

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bellevue Group's SGMO Position: Q4 2020 in Review

Bellevue Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2020, closing a stake of 3,850,000 shares — an estimated $36.4M sold.

Bellevue Group first reported a position in SGMO in Q2 2019 and held it in 6 quarters. The position peaked at $39.3M in Q2 2019. 223 funds tracked by Wall St. Rank hold SGMO as of Q4 2020.

  • Bellevue Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2020 after selling out during the quarter.
  • Bellevue Group sold 3,850,000 SANGAMO THERAPEUTICS INC shares in Q4 2020, an estimated $36.4M.
  • Bellevue Group first reported a position in SANGAMO THERAPEUTICS INC in Q2 2019 and held it in 6 quarters.
  • Bellevue Group's SANGAMO THERAPEUTICS INC position peaked at $39.3M in Q2 2019.
  • 223 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2020.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.